The elimination of hepatitis D as a public health problem: Needs and challenges

Abstract

Epidemiology; Hepatitis D virus; Public health

Epidemiología; Virus de la hepatitis D; Salud pública

Epidemiologia; Virus de l'hepatitis D; Salut Pública

Infection with hepatitis D virus leads to liver disease and cancer most rapidly of all hepatitis viruses. However, knowledge about hepatitis D remains poor and the burden and impact are underestimated, even though some 12–15 million people mainly in low- and middle-income countries may be affected. Its epidemiology is changing, with increasing migration leading to increased risks of infection and disease. A recent Viral Hepatitis Prevention Board meeting reviewed the current epidemiological status, improvements in diagnostic testing, advances in the development of novel antiviral agents in phase III trials and the need for a greater public health response, such as new guidelines and recommended testing of all people newly identified as infected with hepatitis B virus for hepatitis D virus infection. It identified issues and needs for attention with regard to prevention, diagnosis and treatment.

The VHPB is supported by unrestricted grants from the vaccine industry (GlaxoSmithKline Biologicals, Sanofi Pasteur, Merck and Gilead), but remains strict operational/scientific independence and editorial control. Speakers, neither board members are paid for their participation.